US biopharmaceutical research companies are currently developing 180 new medicines to help the nearly 400 million people worldwide who suffer from diabetes, says a new industry report.

The medicines in development are all either in clinical trials or under review by the Food and Drug Administration (FDA), and they include 30 potential new treatments for type 1 diabetes, 100 for type 2 and 52 for diabetes-related conditions, according to the report, from the Pharmaceutical Research and Manufacturers of America (PhRMA).